Author: gchss

Recent education identified fibroblasts growth foundation (FGF)-23 while the an alternative healthy protein with phosphaturic interest. It is mainly released because of the osteocytes that’s today considered to end up being the the very first thing having controls off phosphorus homeostasis.

Whenever GFR falls, this new phosphorus clearance decreases rather, resulting in phosphorus storage. So it hyperphosphatemia, subclinical whenever estimated GFR try >29 mL/minute, is believed to be the main cause of secondary hyperparathyroidism (Fig. 2). Phosphorus induces PTH hormonal of the step three elements:

Induction of mild hypocalcemia by precipitating with calcium as CaHPO_cuatro. Hypocalcemia also results from decreased calcium release from bone pools.

Stimulation away from FGF-23, which leads to severe inhibition of just one-? hydroxylase and depressed level of step 1,twenty five dihydroxyvitamin D. 9 The newest downregulation of nutritional D receptors on the parathyroid glands results in vitamin D resistance. Losing bad feedback to the parathyroid glands reasons an effective high PTH top.

PTH secretion is appropriate in this case and, along with FGF-23, can decrease the tubular reabsorption of phosphorus to <15%. This is a relatively steady state: the phosphorus and calcium levels are back to normal but at the expense of high PTH and FGF-23. When GFR falls below 30 mL/min (CKD stage IV), the tubular reabsorption of phosphorus cannot be further lowered, causing more PTH and FGF-23 secretion. Even though tubular reabsorption of phosphorus is maximally suppressed, there are too few nephrons left to balance the continuing phosphorus intake. Although PTH is no more active on the kidney, its action on the bone is maintained and continues to promote calcium and phosphorus release. The end result is a vicious cycle in which high phosphorus causes PTH secretion and PTH causes more hyperphosphatemia.

Effects

Secondary hyperparathyroidism is a very early disease and its diagnosis and treatment is crucial in the management of patients with CKD. Levin et al 10 demonstrated that the PTH starts to increase as early as the beginning of CKD stage III (estimated GFR, <60 mL/min), along with normal levels of serum calcium and phosphorus.

The effect of secondary hyperparathyroidism on mortality was thought to be mainly caused by hyperphosphatemia. The last phase of the Dialysis Outcomes and Practice Patterns Study identified hyperphosphatemia (PO₄ > 6.1 mg/dL), hypercalcemia (Ca > 10 mg/dL), and high PTH (>600 pg/mL) as 3 independent risk factors for all-cause and cardiovascular mortality, with hazard ratios of 1.18, 1.16, and 1.21, respectively. 11 Moreover, it is known that a calcium-phosphorus product >72 mg 2 /dL 2 is associated with a 34% increased risk of mortality and metastatic calcification. (more…)